Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
This study has been completed.
Information provided by:
Office of Rare Diseases (ORD)
First received: February 24, 2000
Last updated: June 23, 2005
Last verified: December 2001
I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.
|Study Design:||Primary Purpose: Treatment|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Office of Rare Diseases (ORD):
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004762
Sponsors and Collaborators
|Study Chair:||Paul J. Pockros||Scripps Clinic|